Bupropion HCl ER Controlled Substance Status and Mechanism of Action
Bupropion HCl ER is NOT a controlled substance 1. It functions as an antidepressant that works by inhibiting the reuptake of norepinephrine and dopamine in the brain, without affecting serotonin 1.
Controlled Substance Classification
The FDA explicitly states that bupropion is not classified as a controlled substance 1. While studies in individuals with a history of drug abuse showed mild amphetamine-like activity at high doses (400 mg single dose), the recommended daily dosages when taken as prescribed are not significantly reinforcing to stimulant abusers 1. However, there have been reports of abuse when the medication is crushed and inhaled or injected parenterally, which can lead to seizures and death 1.
Mechanism of Action
Bupropion works primarily through dual inhibition of norepinephrine and dopamine reuptake 1, 2. The drug is a relatively weak inhibitor of neuronal uptake of these neurotransmitters and does not inhibit monoamine oxidase or serotonin reuptake 1. This unique mechanism distinguishes it from:
- Selective serotonin reuptake inhibitors (SSRIs) - which target serotonin
- Tricyclic antidepressants - which have broader receptor effects
- MAO inhibitors - which prevent neurotransmitter breakdown
Active Metabolites
Bupropion undergoes extensive hepatic metabolism, producing three active metabolites 1:
- Hydroxybupropion (formed via CYP2B6): Half-life ~20 hours, approximately 50% as potent as parent drug
- Threohydrobupropion: Half-life ~37 hours, approximately 20% as potent
- Erythrohydrobupropion: Half-life ~33 hours, approximately 20% as potent
At steady state, these metabolites reach plasma concentrations equal to or higher than bupropion itself, contributing significantly to the drug's overall therapeutic effect 1.
FDA-Approved Indications
Bupropion is FDA-approved for 3:
- Major depressive disorder (at 300 mg daily)
- Smoking cessation 4
- Seasonal affective disorder
Off-Label Uses Supported by Guidelines
Key Safety Considerations
Seizure Risk
Bupropion lowers the seizure threshold and should be avoided in patients with 3, 4:
- Epilepsy or seizure disorders
- Brain metastases or stroke history
- Eating disorders (bulimia, anorexia)
- Abrupt alcohol or benzodiazepine withdrawal
The maximum recommended dose is 300 mg daily for the extended-release formulation to minimize seizure risk 4.
Neuropsychiatric Effects
Monitor for development or worsening of 3:
- Depression
- Suicidal ideation/behavior (especially in patients <24 years old)
- Hostility or agitation
- Psychotic symptoms (rare but reported) 6
Drug Interactions
- Contraindicated with MAO inhibitors (within 14 days) 3
- Inhibits CYP2D6: May reduce clearance of drugs metabolized by this enzyme 7
- Avoid with tamoxifen (reduces tamoxifen efficacy) 4
Advantages Over Other Antidepressants
Bupropion has a favorable side effect profile compared to SSRIs 2, 8:
- Minimal sexual dysfunction (lowest among antidepressants)
- No weight gain (may actually promote weight loss)
- Low sedation risk
- May improve energy and concentration
This makes it particularly useful for patients who have experienced these side effects with serotonergic antidepressants 3.